Patient Subgroup Outcomes with GPRC5D Bispecifics

Opinion
Video

Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.

Recent Videos
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content